首页> 美国卫生研究院文献>SAGE Choice >Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries
【2h】

Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries

机译:注意间隔!国家内部和国家之间公布的成本效益估算中与变化有关的因素的多层次分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background. Published cost-effectiveness estimates can vary considerably, both within and between countries. Despite extensive discussion, little is known empirically about factors relating to these variations. >Objectives. To use multilevel statistical modeling to integrate cost-effectiveness estimates from published economic evaluations to investigate potential causes of variation. >Methods. Cost-effectiveness studies of statins for cardiovascular disease prevention were identified by systematic review. Estimates of incremental costs and effects were extracted from reported base case, sensitivity, and subgroup analyses, with estimates grouped in studies and in countries. Three bivariate models were developed: a cross-classified model to accommodate data from multinational studies, a hierarchical model with multinational data allocated to a single category at country level, and a hierarchical model excluding multinational data. Covariates at different levels were drawn from a long list of factors suggested in the literature. >Results. We found 67 studies reporting 2094 cost-effectiveness estimates relating to 23 countries (6 studies reporting for more than 1 country). Data and study-level covariates included patient characteristics, intervention and comparator cost, and some study methods (e.g., discount rates and time horizon). After adjusting for these factors, the proportion of variation attributable to countries was negligible in the cross-classified model but moderate in the hierarchical models (14%−19% of total variance). Country-level variables that improved the fit of the hierarchical models included measures of income and health care finance, health care resources, and population risks. >Conclusions. Our analysis suggested that variability in published cost-effectiveness estimates is related more to differences in study methods than to differences in national context. Multinational studies were associated with much lower country-level variation than single-country studies. These findings are for a single clinical question and may be atypical.
机译:>背景。在国家内部或国家之间,发布的成本效益估算可能有很大差异。尽管进行了广泛讨论,但从经验上对与这些变化有关的因素知之甚少。 >目标。要使用多级统计模型来整合已发布的经济评估中的成本效益估算,以调查可能的变化原因。 >方法。通过系统评价确定了他汀类药物预防心血管疾病的成本效益研究。从报告的基本案例,敏感性和亚组分析中提取了增量成本和效果的估计值,这些估计值按研究和国家进行了分组。开发了三个双变量模型:用于容纳来自跨国研究的数据的交叉分类模型;将在国家级别分配给单个类别的跨国数据的分层模型,以及排除跨国数据的分层模型。不同水平的协变量来自文献中建议的一长串因素。 >结果。我们发现67项研究报告了涉及23个国家的2094项成本效益估算(6项研究报告了1个以上的国家)。数据和研究水平的协变量包括患者特征,干预和比较费用,以及一些研究方法(例如贴现率和时间跨度)。在对这些因素进行调整之后,归因于国家的差异比例在交叉分类模型中可忽略不计,但在分层模型中则为中等(占总方差的14%-19%)。改善层次模型拟合的国家/地区变量包括收入和医疗保健财务,医疗保健资源和人口风险的度量。 >结论。我们的分析表明,公布的成本效益估算的可变性更多地与研究方法的差异有关,而与国家背景的差异有关。与单国研究相比,跨国研究与较低的国家级差异相关。这些发现仅针对单个临床问题,可能是非典型的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号